Synthetic Biologics, Inc. (SYN)
EBITDA Growth
54.92%
TTM · Period ending:
SYN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported54.92%period ending
Latest reported54.92%period ending
SYN TTM EBITDA YoY % (-69.23% → 54.92%)
Year-over-year change
High-resolution chart · PNG
SYN ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 54.9202% | |
| -53.6305% | |
| -5.0068% | |
| 9.4204% | |
| -4.962% | |
| -12.4688% | |
| -27.8728% | |
| -35.6976% | |
| -46.1484% | |
| -75.9691% | |
| -79.9327% | |
| -68.3543% | |
| -43.7348% | |
| -1.2697% | |
| 29.3753% | |
| 34.8371% | |
| 34.515% | |
| 27.9674% | |
| -1.7298% | |
| -1.5386% | |
| -15.0374% | |
| -113.6344% | |
| 4.6944% | |
| 0.5909% | |
| 12.2856% | |
| 65% | |
| 18.7248% | |
| 24.6082% | |
| 44.9111% | |
| 43.5019% | |
| 48.4593% | |
| 54.7065% | |
| 37.9411% | |
| 8.8571% | |
| 8.4791% | |
| -48.9551% | |
| -120.932% | |
| -123.8732% | |
| -133.9683% | |
| -103.5632% | |
| -61.0233% | |
| 12.9711% | |
| 14.5389% | |
| 23.0019% | |
| 27.8212% | |
| -149.3229% | |
| -158.5442% | |
| -156.8182% | |
| -113.9532% | |
| -43.8773% | |
| -39.5674% | |
| -186.7124% | |
| -492.099% | |
| -259.1974% | |
| -254.0647% | |
| 26.1266% | |
| 59.8189% | |
| 50.6692% | |
| 62.9814% | |
| 31.3524% | |
| 50.8755% | |
| 65.0384% | |
| 59.6152% | |
| 50.9001% | |
| 29.8401% | |
| 15.4717% | |
| -13.0124% | |
| -42.152% | |
| -110.8023% | |
| -1,940.9315% | |
| -1,502.3686% | |
| -146.5942% | |
| -114.9605% | |
| -101.1166% | |
| 625.3682% | |
| 374.7641% | |
| 207.2022% | |
| 41.7348% | |
| 8.7202% | |
| -31.9939% | |
| -75.0207% | |
| -86.1256% | |
| -63.3766% | |
| 53.3546% | |
| 60.7411% | |
| 65.6167% | |
| 65.5446% | |
| -272.9105% | |
| -299.4421% | |
| -359.4534% | |
| -255.6485% | |
| 12.963% | |
| 27.8689% | |
| 56.3218% | |
| 47.8261% | |
| 44.898% | |
| 35.7895% | |
| -11.5385% | |
| -35.2941% | |
| -48.4848% |